Findings seen in patients previously treated with platinum-based chemotherapy and immunotherapy whose tumors highly expressed CEACAM5

Perioperative nivolumab showed event-free survival benefit from time of surgery compared with neoadjuvant nivolumab

10-year lung cancer-specific survival of 80 percent reported in 2006 persisted, with 81 percent survival at 20 years

At three, six, and nine years, overall survival was 64, 43, and 26 percent and progression-free survival was 88, 78, and 78 percent, respectively

Furthermore, consistency of lung cancer may be an important predictor of survival

Patients with stage IV non-small cell lung cancer who are 65 years of age or older may be undertreated

Risk for recurrence increased with surgical delay beyond 12 weeks; overall survival improved with surgery within 12 weeks